Literature DB >> 28499247

NLRC5 deficiency promotes myocardial damage induced by high fat diet in mice through activating TLR4/NF-κB.

Shu-Ren Ma1, Xiong-Wei Xie2.   

Abstract

The metabolic syndrome could be induced by high fat diet, leading to cardiovascular diseases, such as myocardial damage. Inflammation response and oxidative stress have been reported to be involved in high fat-induced heart injury, and the molecular mechanism is not fully understood. The NOD-like protein family member, NLRC5, could interact with IKKα to inhibit IKK complex activation. In our study, high fat diet-feeding mice showed cardiac fibrosis, inflammation and oxidative stress through collagen accumulation, TLR4/NF-κB and MAPKs signaling pathways activation. NLRC5 knockout mice fed with high fat showed accelerated fibrosis and inflammation response by promoting α-SMA, Collagen I, Collagen III, TLR4/MyD88, phosphorylated IKKα, IκBα and NF-κB expression. And no effect on oxidative stress was observed in wild type and NLRC5-deficiency samples in in vivo studies. Moreover, NLRC5-knockout and -knockdown cardiac muscle cells challenged with LPS also exhibited aggravated fibrosis levels and inflammatory response without any influences on ROS production in in vitro studies. In conclusion, the findings indicated that NLRC5 showed important effects on high fat-induced heart injury via fibrosis and inflammation modulation, providing an essential target for improving myocardial damage induced by high fat diet.
Copyright © 2017. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Fibrosis; Inflammation; Myocardial damage; NLRC5; TLR4/NF-κB

Mesh:

Substances:

Year:  2017        PMID: 28499247     DOI: 10.1016/j.biopha.2017.03.062

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

1.  Omentin inhibits the resistin-induced hypertrophy of H9c2 cardiomyoblasts by inhibiting the TLR4/MyD88/NF-κB signaling pathway.

Authors:  Xiaoliang Yan; Lin Wu; Min Gao; Pengjie Yang; Jinjing Yang; Yongzhi Deng
Journal:  Exp Ther Med       Date:  2022-02-17       Impact factor: 2.447

2.  NLRC5 enhances autophagy via inactivation of AKT/mTOR pathway and ameliorates cardiac hypertrophy.

Authors:  Bayinsilema Ba; Abudoukelimu Mayila; Yankai Guo; Jie Xu; Shifeng Xing; GuiQiu Cao
Journal:  Int J Exp Pathol       Date:  2021-11-21       Impact factor: 1.925

3.  AEG-1 deletion promotes cartilage repair and modulates bone remodeling-related cytokines via TLR4/MyD88/NF-κB inhibition in ovariectomized rats with osteoporosis.

Authors:  Yuan Zhang; Qing Zhao
Journal:  Ann Transl Med       Date:  2020-10

4.  NLRC5 attenuates inflammatory response in IL-1β-stimulated human osteoarthritis chondrocytes through the NF-κB signaling pathway.

Authors:  Yiping Mu; Yang Zhang; Jie Wu; Qi Li
Journal:  Aging (Albany NY)       Date:  2021-08-26       Impact factor: 5.682

5.  The Regulatory NOD-Like Receptor NLRC5 Promotes Ganglion Cell Death in Ischemic Retinopathy by Inducing Microglial Pyroptosis.

Authors:  Yang Deng; Yunzhao Fu; Longxiang Sheng; Yixin Hu; Lishi Su; Jiawen Luo; Chun Yan; Wei Chi
Journal:  Front Cell Dev Biol       Date:  2021-05-20

6.  Epigenome-Wide Association Study of Soluble Tumor Necrosis Factor Receptor 2 Levels in the Framingham Heart Study.

Authors:  Michael M Mendelson; Roby Johannes; Chunyu Liu; Tianxiao Huan; Chen Yao; Xiao Miao; Joanne M Murabito; Josée Dupuis; Daniel Levy; Emelia J Benjamin; Honghuang Lin
Journal:  Front Pharmacol       Date:  2018-04-24       Impact factor: 5.810

7.  NLRC5 alleviated OGD/R-induced PC12-cell injury by inhibiting activation of the TLR4/MyD88/NF-κB pathway.

Authors:  Zhen Zhang; Yuhan Sun; Xin Chen
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

8.  LncRNA MALAT1 prevents the protective effects of miR-125b-5p against acute myocardial infarction through positive regulation of NLRC5.

Authors:  Zhiyong Liu; Jing Liu; Ying Wei; Jing Xu; Zhaoning Wang; Peng Wang; Hao Sun; Zhijing Song; Qian Liu
Journal:  Exp Ther Med       Date:  2019-12-09       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.